Pathogenesis and treatment of lipodystrophy: what clinicians need to know.

Pathogenesis and treatment of lipodystrophy: what clinicians need to know. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Pathogenesis and treatment of lipodystrophy: what clinicians need to know. Abstract Text:

The pathogenesis of lipodystrophy in HIV-infected patients is likely multifactorial, involving effects of antiretroviral medications, HIV itself, as well as genetic and other host factors. Protease inhibitors have been associated with fat accumulation, and the nucleoside analogue reverse transcriptase inhibitors (nRTIs) stavudine, didanosine, and zidovudine have been associated with fat loss (lipoatrophy). Strategies that have met with some success in reducing central fat accumulation include treatment with growth hormone or growth hormone-releasing hormone. Strategies that have met with some success for lipoatrophy include switching from nRTIs associated with lipoatrophy or starting treatment with regimens that include drugs associated with lower risk of lipoatrophy (tenofovir, abacavir, lamivudine, emtricitabine). This article summarizes a presentation on lipodystrophy made by Fred R. Sattler, MD, at an International AIDS Society-USA Continuing Medical Education course in Washington, DC, in May 2008. The original presentation is available as a Webcast at www.iasusa.org.

Pathogenesis and treatment of lipodystrophy: what clinicians need to know. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE: 2008 Oct-Nov

Pathogenesis and treatment of lipodystrophy: what clinicians need to know. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Topics in HIV medicine : a publication of the Inte

VOLUME: 16

Page Numbers: 127-33

Journal Abbreviation:

ISSN: 1542-8826

DAY: 7

MONTH: 10

YEAR: 2008

Pathogenesis and treatment of lipodystrophy: what clinicians need to know. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100954650

Pathogenesis and treatment of lipodystrophy: what clinicians need to know. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Pathogenesis and treatment of lipodystrophy: what clinicians need to know. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Pathogenesis and treatment of lipodystrophy: what clinicians need to know.

AFFILIATION: Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Top HIV Med

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Pathogenesis and treatment of lipodystrophy: what clinicians need to know Related Publications

• Butyrolactone I Derivatives from Aspergillus terreus Carrying an Unusual Sulfate Moiety.
• Cell cycle regulation by oncogenic tyrosine kinases in myeloid neoplasias: from molecular redox mechanisms to health implications.
• Comparison of RRR-alpha- and all-rac-alpha-tocopherol uptake by permanent rat skeletal muscle myoblasts (L6 cells): effects of exogenous lipoprotein lipase.
• Connection piece for hearing device support hook.
• Decreasing asthmagens in hospitals.
• Dynamic effects on j-couplings across hydrogen bonds in proteins.
• Improving outcomes in pediatric procedural sedation.
• Inhibition of lung carcinoma cell growth by high density lipoprotein-associated alpha-tocopheryl-succinate.
• Lipoprotein-associated alpha-tocopheryl-succinate inhibits cell growth and induces apoptosis in human MCF-7 and HBL-100 breast cancer cells.
• New Abietane Diterpenoids from the Mangrove Avicennia marina.
• New report on decreasing asthmagens in hospitals.
• Our bodies and the legacy of "better living through chemistry.
• Pathogenesis and treatment of lipodystrophy: what clinicians need to know.
• Reliability of maximal voluntary muscle strength and power testing in older men.
• Results of alloarthroplasty of the hip joint.
• Site-specific variations of carbonyl chemical shift anisotropies in proteins.
• Structure and functional analysis of the MYND domain.
• Structure, derivatization, and antitumor activity of new griseusins from Nocardiopsis sp.
• Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).
• The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes.
• [Demonstration of I/i- and Pr-antigens on lymphocytes by cold agglutinins (proceedings)]
• [Esophagus carcinoma in young adults.]
• [Experiences with a barbituric acid-free hypnotic combination.]
• [Not Available.]